February 28, 2008, Toronto, Ont., Canada--Theralase Technologies, a developer, manufacturer and distributor of therapeutic medical laser systems, has achieved positive research and development results in the destruction of individual cancer cell lines. This research is aimed at combining patented photodynamic compounds (PDCs), under exclusive worldwide license to Theralase, with the company's patented bio-feedback laser technology for the selective destruction of cancers, bacteria, viruses, and fat cells.
Theralase, in conjunction with University Health Network, Virginia Tech and with financial support from the Ontario Centres of Excellence's Centre for Photonics, commenced a project in July 2007 focused on assessing the therapeutic potential of various PDCs in combination with the company's patented laser technology. The TLC-3000 project involves progressive assessment of the destruction of cancerous cells in: individual cancer cell lines, small animals, large animals and humans.
"Theralase is pleased to achieve the first milestone in our PDC project aimed at combining the power of PDCs with our laser technology in the destruction of cancerous cells," said Roger Dumoulin-White, President and CEO of Theralase. "We expect to release the final results in a publication or scientific symposium in the next few months."
Independent laboratory research has now confirmed significant efficacy of all three PDCs, under assessment, in successfully killing brain cancer and colon cancer cell lines. The PDCs employed in the trials have proven the ability to selectively target cancerous cells over cells derived from healthy tissue. Additional cancer cell lines and various bacterial species will be evaluated in the next stage of the project to determine cell kill by the PDCs.